FUL

Analyst Note: H.B. Fuller Company (FUL)

Date: 2026-06-13 Current Price: $64.86

1. Structural Readiness

State: Context-only Conservative Entry: — (Awaiting confirmed breakout) Current Price: $64.86 Extension: — ATR at Breakout: — ATR Current: 3.4% (Productive) Pivot Strength: —

Structural Assessment:

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Secular Exposure: None named at this date.

There is NO named macro or secular thesis attached to FUL as of 2026-06-13. This is a tactical, setup-led name. Conviction must be derived strictly from the quality of the structural setup (the forming coil) and the underlying business fundamentals provided in the evidence base. No external thematic drivers (e.g., "green energy boom" or "supply chain reshoring") are currently assigned to this specific setup in the source data. The investment case rests on the company's ability to execute its guidance and the technical resolution of the current price structure.

3. Business Overview

Company Profile: H.B. Fuller Company is a leading worldwide formulator, manufacturer, and marketer of adhesives, sealants, and other specialty chemical products. Sales operations span 34 countries across North America, Europe, Latin America, Asia Pacific, India, the Middle East, and Africa. The company serves a diverse set of customers, including manufacturers of food and beverage, hygiene products, clothing, major appliances, electronics, automobiles, aerospace, and construction materials. No single customer accounts for more than 10% of consolidated net revenue.

Operating Segments: The company operates through three reportable segments:

• Hygiene, Health and Consumable Adhesives (HHC): Serves disposable diapers, feminine hygiene, medical garments, and packaging.
• Engineering Adhesives: Specializes in high-performance industrial adhesives (reactive, light-cure, silicone, polyurethane) for appliances, transportation, electronics, and aerospace.
• Building Adhesive Solutions: Delivers products for construction, including caulking compounds and sealants for professional trades and consumers.

Recent Performance & Guidance (Source: Earnings Transcript, 2026-03-26):

• Revenue Guidance: Management expects full-year 2026 net revenue to be up mid-single digits and organic revenue up low single digits versus fiscal 2025. This reflects updated pricing actions and anticipated market share gains.
• Profitability Guidance: Adjusted EBITDA for fiscal 2026 is expected to be in the range of $645 million to $675 million.
• Q2 2026 Outlook: Net revenue expected up low single digits; Adjusted EBITDA expected in the range of $175 million to $185 million.
• Q1 2026 Results:
• Net revenue decreased 2.3% year-over-year (driven by a 7.2% volume decline, partially offset by 3.6% currency, 0.7% M&A, and 0.6% pricing).
• Organic revenue decreased 6.6%.
• Segment Performance: HHC organic revenue declined 10% (challenging environment, inventory tightening, consumer shift to lower-cost alternatives). Engineering Adhesives declined 2.0%. Building Adhesive Solutions declined 5.1%.
• Margin Expansion: Gross profit margin increased 180 basis points, driven by higher product pricing, lower raw material costs, acquisitions, and restructuring.
• M&A Activity: The 0.7% revenue increase from M&A was attributed to the acquisition of GEM, Medifill, ND Industries Taiwan, and ND Industries Turkey.

Supply Chain Context: Management noted receiving over 40 force majeure letters from suppliers in recent weeks, indicating significant chemical production capacity decreases and disrupted tanker routes. Management views this disruption as a unique opportunity to support existing customers and gain market share, positioning the company for improved volume growth in the future.

4. Archetype and Conviction

Archetype: Growth Leader (Source: Layer A) *Note: While recent organic growth was negative in Q1, the archetype classification reflects the company's positioning as a formulator capable of margin expansion and market share capture through pricing and M&A, rather than a pure volume-driven cyclical recovery.*

Conviction Stack Analysis:

• Thesis Strength: Low (Tactical/Setup-led only; no macro tailwinds).
• Evidence Quality: High. The evidence base is robust, containing specific guidance ranges, segment-level performance data, and clear management commentary on supply chain dynamics.
• Setup Readiness: Incomplete. The setup is Forming, not Confirmed. The price is holding above the support level, but the breakout trigger has not occurred.
• Rerating Potential: Dependent on the execution of the "mid-single digit" revenue growth and the realization of the "market share gains" mentioned in guidance. The 180 bps margin expansion in Q1 provides a strong foundation for the EBITDA guidance.

Valuation Context: The financial spine indicates a forward consensus EPS of $4.72 for FY1 and $5.15 for FY2. At a current price of $64.86, the stock trades at approximately 13.7x FY1 consensus and 12.6x FY2 consensus. This valuation appears reasonable given the guidance for EBITDA growth and margin expansion, though the lack of a named secular thesis limits the multiple expansion potential.

5. Invalidations, Strengtheners, and Gaps

Invalidation Triggers:

• Fundamental: A significant miss on the Q2 2026 guidance (Revenue < low single digit growth or EBITDA < $175M) or a reversal of the margin expansion trend (e.g., raw material costs rising faster than pricing power).
• Operational: Failure to capture market share from competitors facing supply disruptions, or a prolonged inability to pass through cost increases.

Strengtheners:

• Technical: A confirmed breakout above the coil resistance level with volume expansion.
• Fundamental: Confirmation that the "market share gains" are materializing in Q2, offsetting the volume declines in HHC.
• Operational: Successful integration of recent M&A (GEM, Medifill, etc.) contributing to top-line growth beyond the 0.7% seen in Q1.

Evidence Gaps:

• Specific Price Targets: No explicit management guidance on stock price or buyback levels.
• Detailed Q2 Data: While Q2 guidance is provided, actual Q2 results are not yet in the evidence base (as of the transcript date of March 26, 2026, this is forward-looking).
• Supply Chain Resolution: The duration and severity of the "force majeure" disruptions are not quantified beyond the count of 40 letters.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Management guidance for mid-single digit revenue growth and $645-675M EBITDA; 180 bps gross margin expansion in Q1 driven by pricing and cost control; Supply chain disruptions creating a potential market share opportunity. Key risks: HHC segment volume decline of 10% YoY reflecting consumer affordability pressure; Technical setup is "Forming" and not yet confirmed; No named secular thesis to support multiple expansion. Sizing hint: Position size should reflect the "Forming" status; treat as a partial position awaiting breakout confirmation. Expected path: Management expects revenue to grow mid-single digits and EBITDA to reach the $645-675M range as pricing actions and market share gains offset volume headwinds. Expected horizon: 3 to 6 months for the technical setup to resolve (breakout or invalidation) and for Q2 results to validate guidance.